November is National Alzheimer’s Disease (AD) Awareness Month in the US.
AD is the most common
form of dementia: 60-70% of all dementia cases are AD. This is one of the
cruelest and life-threatening diseases that impacts memory, movement, behavior
and even thinking.
There is still no cure for AD. However, patients can potentially reduce the
symptoms with the help of medications.
GCT is a global provider of services for CNS and Neurology clinical
studies.
GCT President, Dr Jeffrey T. Apter is a Key Opinion Leader (KOL) in Alzheimer’s Disease. He has been a research collaborator
in the Departments of Psychology and the member of the New Jersey Alzheimer
Association Scientific Advisory Board, publishing of over 30 articles in the
areas of psychiatric and Alzheimer’s research.
Since 2001, GCT conducted numerous AD trials helping pharma and biotech
company with their search for medication to cure the disease of fight its
symptoms.
Please contact bd@gctrilas.com for
more information about AD research.